Resilience Capacity Update July 2025: Large Molecule Drug Substance

Resilience is an end-to-end CDMO specializing in biologics development and manufacturing serving small, mid-size and large pharmaceutical and biotechnology companies. Within the Resilience network, we have supported over 6 commercial programs with products in over 50 markets worldwide. In this update, you will hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support Large Molecule programs from early phase through clinical and commercial manufacturing.